FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950872861> ?p ?o ?g. }

• W2950872861 abstract "Background The ultimate goals for rheumatoid arthritis (RA) treatment are to achieve disease activity control and the best potential health state throughout the course of disease.1 In prior analyses of the Phase 3 trial, RA-BEAM (NCT01710358), baricitinib was associated with significant clinical improvements and patient-reported pain relief in RA patients (pts) who had had an inadequate response to methotrexate.2,3 The additional benefits of pain relief when inflammation is controlled are not well characterized. Objectives To quantify the contribution of pain relief to other PROs, fatigue, physical function, and quality of life, in pts who achieved control of inflammation, defined as swollen joint count (SJC) ≤1 and C-reactive protein (CRP) ≤1 mg/dL, at Week (Wk) 24 in a post hoc, pooled analysis of RA-BEAM. Methods Among pts with inflammation control, PROs were compared between pts who also achieved thresholds of pain relief at Wk 24 vs those who did not. Pain was measured with a visual analogue scale (VAS, range: 0-100 mm) and divided into ≤20, >20, ≤40, >40 mm.4,5 PROs included: the Health Assessment Questionnaire-Disability Index (HAQ-DI) normative value ( Results Of the total 1305 patients in RA-BEAM, 371 pts treated with adalimumab (121/330), baricitinib (187/487), or placebo (63/488) and background methotrexate achieved inflammation control at Wk 24. Among patients who achieved inflammation control, those who also achieved each pain relief threshold were statistically significantly more likely (p Conclusion When inflammation is controlled (SJC ≤1 and CRP ≤1 mg/dL), more pain relief is associated with better physical function, quality of life, and reduced fatigue. This may support consideration of pain relief as an additional goal of therapy, even when inflammation is controlled. Further investigation should evaluate this benefit with other patient populations and outcomes. Reference [1] Smolen, et al. ARD 2017; 76: 960-77; 2. Taylor, et al. NEJM 2017; 376: 652-62; 3. Taylor, et al. Arthritis Rheumatol 2017; 69 (Suppl 10); 4. Wolfe & Michaud, J Rheumatol 2007; 34: 1674-83; 5. Tubach, et al. Arthritis Care Res 2012; 64:1699-707. Disclosure of Interests Mart van de Laar Grant/research support from: Eli Lilly, Pfizer, Merck, AbbVie and Janssen Cilag, Consultant for: Sanofi Genzym, Eli Lilly, Pfizer, Merck, Abbvie and Janssen Cilag, Speakers bureau: Eli Lilly, Pfizer and Janssen Cilag, Janet Pope Consultant for: Eli Lilly and Company, Yvonne Lee Shareholder of: Express Scripts, Grant/research support from: Pfizer, Bruno Fautrel Grant/research support from: AbbVie, Lilly, MSD, Pfizer, Consultant for: AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, Medac, MSD, NORDIC Pharma, Novartis, Pfizer, Roche, Sanofi-Aventis, Sanofi Genzyme, SOBI, UCB, Kei Ikeda: None declared, Amanda Quebe Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Xiang Zhang Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Carol Gaich Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Francesco de Leonardis Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Jeffrey Lisse Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Jennifer Workman Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Peter C. Taylor Grant/research support from: Celgene, Galapagos, Eli Lilly, UCB, Consultant for: AbbVie, Galapagos, Gilead, Eli Lilly, Pfizer Inc" @default.
• W2950872861 created "2019-06-27" @default.
• W2950872861 creator A5012049936 @default.
• W2950872861 creator A5015032522 @default.
• W2950872861 creator A5023213876 @default.
• W2950872861 creator A5025720630 @default.
• W2950872861 creator A5025726530 @default.
• W2950872861 creator A5031804038 @default.
• W2950872861 creator A5049261212 @default.
• W2950872861 creator A5052807793 @default.
• W2950872861 creator A5055056502 @default.
• W2950872861 creator A5055606961 @default.
• W2950872861 creator A5059078541 @default.
• W2950872861 creator A5072897343 @default.
• W2950872861 date "2019-06-01" @default.
• W2950872861 modified "2023-09-23" @default.
• W2950872861 title "AB0287 BENEFITS OF PAIN RELIEF ON FATIGUE, FUNCTION, AND QUALITY OF LIFE WHEN JOINT INFLAMMATION IS CONTROLLED IN PATIENTS WITH RA" @default.
• W2950872861 doi "https://doi.org/10.1136/annrheumdis-2019-eular.542" @default.
• W2950872861 hasPublicationYear "2019" @default.
• W2950872861 type Work @default.
• W2950872861 sameAs 2950872861 @default.
• W2950872861 citedByCount "0" @default.
• W2950872861 crossrefType "proceedings-article" @default.
• W2950872861 hasAuthorship W2950872861A5012049936 @default.
• W2950872861 hasAuthorship W2950872861A5015032522 @default.
• W2950872861 hasAuthorship W2950872861A5023213876 @default.
• W2950872861 hasAuthorship W2950872861A5025720630 @default.
• W2950872861 hasAuthorship W2950872861A5025726530 @default.
• W2950872861 hasAuthorship W2950872861A5031804038 @default.
• W2950872861 hasAuthorship W2950872861A5049261212 @default.
• W2950872861 hasAuthorship W2950872861A5052807793 @default.
• W2950872861 hasAuthorship W2950872861A5055056502 @default.
• W2950872861 hasAuthorship W2950872861A5055606961 @default.
• W2950872861 hasAuthorship W2950872861A5059078541 @default.
• W2950872861 hasAuthorship W2950872861A5072897343 @default.
• W2950872861 hasBestOaLocation W29508728611 @default.
• W2950872861 hasConcept C126322002 @default.
• W2950872861 hasConcept C14184104 @default.
• W2950872861 hasConcept C142724271 @default.
• W2950872861 hasConcept C159110408 @default.
• W2950872861 hasConcept C1862650 @default.
• W2950872861 hasConcept C204787440 @default.
• W2950872861 hasConcept C27081682 @default.
• W2950872861 hasConcept C2776914184 @default.
• W2950872861 hasConcept C2777077863 @default.
• W2950872861 hasConcept C2777575956 @default.
• W2950872861 hasConcept C2779951463 @default.
• W2950872861 hasConcept C2780132546 @default.
• W2950872861 hasConcept C2781059491 @default.
• W2950872861 hasConcept C71924100 @default.
• W2950872861 hasConcept C90924648 @default.
• W2950872861 hasConceptScore W2950872861C126322002 @default.
• W2950872861 hasConceptScore W2950872861C14184104 @default.
• W2950872861 hasConceptScore W2950872861C142724271 @default.
• W2950872861 hasConceptScore W2950872861C159110408 @default.
• W2950872861 hasConceptScore W2950872861C1862650 @default.
• W2950872861 hasConceptScore W2950872861C204787440 @default.
• W2950872861 hasConceptScore W2950872861C27081682 @default.
• W2950872861 hasConceptScore W2950872861C2776914184 @default.
• W2950872861 hasConceptScore W2950872861C2777077863 @default.
• W2950872861 hasConceptScore W2950872861C2777575956 @default.
• W2950872861 hasConceptScore W2950872861C2779951463 @default.
• W2950872861 hasConceptScore W2950872861C2780132546 @default.
• W2950872861 hasConceptScore W2950872861C2781059491 @default.
• W2950872861 hasConceptScore W2950872861C71924100 @default.
• W2950872861 hasConceptScore W2950872861C90924648 @default.
• W2950872861 hasLocation W29508728611 @default.
• W2950872861 hasOpenAccess W2950872861 @default.
• W2950872861 hasPrimaryLocation W29508728611 @default.
• W2950872861 hasRelatedWork W2230367379 @default.
• W2950872861 hasRelatedWork W2268500885 @default.
• W2950872861 hasRelatedWork W2549411495 @default.
• W2950872861 hasRelatedWork W2549701246 @default.
• W2950872861 hasRelatedWork W2553598894 @default.
• W2950872861 hasRelatedWork W2553702955 @default.
• W2950872861 hasRelatedWork W2755057696 @default.
• W2950872861 hasRelatedWork W2885462375 @default.
• W2950872861 hasRelatedWork W2909924915 @default.
• W2950872861 hasRelatedWork W2950855053 @default.
• W2950872861 hasRelatedWork W3035200754 @default.
• W2950872861 hasRelatedWork W3045039542 @default.
• W2950872861 hasRelatedWork W3095410646 @default.
• W2950872861 hasRelatedWork W3163991765 @default.
• W2950872861 hasRelatedWork W3164440162 @default.
• W2950872861 hasRelatedWork W3165281389 @default.
• W2950872861 hasRelatedWork W3165327761 @default.
• W2950872861 hasRelatedWork W3165733823 @default.
• W2950872861 hasRelatedWork W3165803692 @default.
• W2950872861 hasRelatedWork W3165824012 @default.
• W2950872861 isParatext "false" @default.
• W2950872861 isRetracted "false" @default.
• W2950872861 magId "2950872861" @default.
• W2950872861 workType "article" @default.